Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

Andrea Tubaro*, Jose E. Batista, Victor W. Nitti, Sender Herschorn, Christopher R. Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)137-154
Number of pages18
JournalTherapeutic Advances in Urology
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 2017

Keywords

  • benign prostatic enlargement
  • benign prostatic hyperplasia
  • LUTS
  • male patients
  • mirabegron
  • overactive bladder
  • URINARY-TRACT SYMPTOMS
  • BENIGN PROSTATIC HYPERPLASIA
  • QUALITY-OF-LIFE
  • DOUBLE-BLIND
  • BETA(3)-ADRENOCEPTOR AGONIST
  • OUTLET OBSTRUCTION
  • 3-ADRENOCEPTOR AGONIST
  • MEN
  • POPULATION
  • IMPACT

Cite this

Tubaro, A., Batista, J. E., Nitti, V. W., Herschorn, S., Chapple, C. R., Blauwet, M. B., Siddiqui, E., Huang, M., & Oelke, M. (2017). Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Therapeutic Advances in Urology, 9(6), 137-154. https://doi.org/10.1177/1756287217702797